CEST Imaging vs. DWI vs. FDG-PET/CT: Therapeutic Effect Prediction for Chemoradiotherapy in Non-Small Cell Lung Cancer Patients
Yoshiharu Ohno1,2, Masao Yui3, Daisuke Takenaka4, Takeshi Yoshikawa4, Kaori Yamamoto3, Masato Ikedo3, Saki Takeda5, Akiyoshi Iwase5, Satomu Hanamatsu1, Yuki Obama1, Hiroyuki Nagata1, Takahiro Ueda1, Hirotaka Ikeda1, Kazuhiro Murayama2, and Hiroshi Toyama1
1Radiology, Fujita Health University School of Medicine, Toyoake, Japan, 2Joint Research Laboratory of Advanced Medical Imaging, Fujita Health University School of Medicine, Toyoake, Japan, 3Canon Medical Systems Corporation, Otawara, Japan, 4Diagnostic Radiology, Hyogo Cancer Center, Akashi, Japan, 5Radiology, Fujita Health University Hospital, Toyoake, Japan
We hypothesize that CEST imaging has a potential for therapeutic effect prediction in NSCLC patients treated with chemoradiotherapy and may be at least as valuable as DWI and FDG-PET/CT. Moreover, combined predictors may improve therapeutic effect prediction capability, when compared with single predictor from MRI or PET/CT. The purpose of this study was to compare the capability of therapeutic effect prediction for chemoradiotherapy among CEST imaging, DWI, FDG-PET/CT and combined predictors from MRI and PET/CT in NSCLC patients.
This abstract and the presentation materials are available to members only;
a login is required.